Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas

Lung Cancer

Volumn 58, Issue 3, 2007, Pages 303-309

  Valbuena, Alberto ^a   Suárez Gauthier, Ana ^b   López Rios, Fernando ^c   López Encuentra, Angel ^c   Blanco, Sandra ^a   Fernández, Pedro L ^d   Sánchez Céspedes, Montserrat ^b   Lazo, Pedro A ^a  

^a CSIC   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

p16; p53; Proliferation; Squamous cell carcinoma; VRK1

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; PROTEIN C JUN; PROTEIN P16; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; VACCINIA RELATED KINASE 1;

ARTICLE; AUTOREGULATION; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MUTATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35748961431     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.06.023     Document Type: Article

References (35)

1. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
2. Nezu J., Oku A., Jones M.H., and Shimane M. Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics 45 (1997) 327-331
3. Lazo PA, Vega FM, Sevilla A. Vaccinia-related kinase-1. Afcs Nature Molecule Page; 2005. doi:10.1038/:mp.a003025.003001.
4. Lopez-Borges S., and Lazo P.A. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene 19 (2000) 3656-3664
5. Barcia R., Lopez-Borges S., Vega F.M., and Lazo P.A. Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. Arch Biochem Biophys 399 (2002) 1-5
6. Schon O., Friedler A., Bycroft M., Freund S., and Fersht A. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323 (2002) 491-501
7. Jabbur J.R., Tabor A.D., Cheng X., Wang H., Uesugi M., Lozano G., and Zhang W. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene 21 (2002) 7100-7113
8. Vega F.M., Sevilla A., and Lazo P.A. p53 Stabilization and accumulation induced by human vaccinia-related kinase 1. Mol Cell Biol 24 (2004) 10366-10380
9. Vega F.M., Gonzalo P., Gaspar M.L., and Lazo P.A. Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development. FEBS Lett 544 (2003) 176-180
10. Kamath R.S., Fraser A.G., Dong Y., Poulin G., Durbin R., Gotta M., Kanapin A., Le Bot N., Moreno S., Sohrmann M., Welchman D.P., Zipperlen P., and Ahringer J. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421 (2003) 231-237
11. Meek D.W. Multisite phosphorylation and the integration of stress signals at p53. Cell Signal 10 (1998) 159-166
12. Valbuena A., Vega F.M., Blanco S., and Lazo P.A. p53 downregulates its activating vaccinia-related kinase 1 forming a new autoregulatory loop. Mol Cell Biol 26 (2006) 4782-4793
13. Santos C.R., Rodriguez-Pinilla M., Vega F.M., Rodriguez-Peralto J.L., Blanco S., Sevilla A., Valbuena A., Hernandez T., van Wijnen A.J., Li F., de Alava E., Sanchez-Cespedes M., and Lazo P.A. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res 4 (2006) 177-185
14. Travis W.D., Brambilla E., Müller-Hermelink H.K., and Harris C.C. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart (2004), IARC Press, Lyon
15. Conde E., Angulo B., Tang M., Morente M., Torres-Lanzas J., Lopez-Encuentra A., Lopez-Rios F., and Sanchez-Cespedes M. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12 (2006) 710-717
16. Rodriguez-Pinilla M., Rodriguez-Peralto J.L., Hitt R., Sanchez J.J., Ballestin C., Diez A., Sanchez-Verde L., Alameda F., and Sanchez-Cespedes M. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 10 (2004) 8486-8492
17. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., and Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52 (1992) 4828-4831
18. Brambilla E., Gazzeri S., Moro D., Lantuejoul S., Veyrenc S., and Brambilla C. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 5 (1999) 243-250
19. Brambilla E., Moro D., Gazzeri S., and Brambilla C. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 188 (1999) 351-360
20. Fernandez P., Carretero J., Medina P.P., Jimenez A.I., Rodriguez-Perales S., Paz M.F., Cigudosa J.C., Esteller M., Lombardia L., Morente M., Sanchez-Verde L., Sotelo T., and Sanchez-Cespedes M. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene 23 (2004) 5084-5091
21. Nichols R.J., and Traktman P. Characterization of three paralogous members of the mammalian vaccinia related kinase family. J Biol Chem 279 (2004) 7934-7946
22. Blanco S., Klimcakova L., Vega F.M., and Lazo P.A. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. FEBS J 273 (2006) 2487-2504
23. Hirsch F.R., Franklin W.A., Gazdar A.F., and Bunn Jr. P.A. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 7 (2001) 5-22
24. Kinzler K.W., and Vogesltein B. Colorectal tumors. In: Kinzler K.W., and Vogesltein B. (Eds). The genetic basis of human cancer (1998), McGraw-Hill, New York 565-587
25. Davidoff A.M., Kerns B.J., Iglehart J.D., and Marks J.R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51 (1991) 2605-2610
26. Prives C., and Hall P.A. The p53 pathway. J Pathol 187 (1999) 112-126
27. Ferreira C.G., Tolis C., and Giaccone G. p53 and chemosensitivity. Ann Oncol 10 (1999) 1011-1021
28. Taylor W.R., and Stark G.R. Regulation of the G2/M transition by p53. Oncogene 20 (2001) 1803-1815
29. Bargonetti J., and Manfredi J.J. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14 (2002) 86-91
30. Sevilla A., Santos C.R., Barcia R., Vega F.M., and Lazo P.A. c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene 23 (2004) 8950-8958
31. Sevilla A., Santos C.R., Vega F.M., and Lazo P.A. Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK. J Biol Chem 279 (2004) 27458-27465
32. Nichols R.J., Wiebe M.S., and Traktman P. The vaccinia-related kinases phosphorylate the N' terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. Mol Biol Cell 17 (2006) 2451-2464
33. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 (2001) 731-737
34. Vernell R., Helin K., and Muller H. Identification of target genes of the p16INK4A-pRB-E2F pathway. J Biol Chem 278 (2003) 46124-46137
35. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., and Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443 (2006) 214-217